Buffett firm slashes J&J stake by 95%; Sanofi shops Israel for consumer health company;

@FiercePharma: Slovenia's Krka expects 2012 profits to fall short, but sees 6% sales hike in 2013; plans hiring, new plants. Article | Follow @FiercePharma

> FDA Commissioner Margaret Hamburg clashed with lawmakers on Capitol Hill yesterday, as she called for clearer FDA authority to regulate compounding pharmacies. Report

> Warren Buffett's Berkshire Hathaway ($BRK.B) unloaded 95% of its stake in Johnson & Johnson ($JNJ) in its latest selloff of the stock. Report

> The U.K.'s cost-effectiveness watchdog gave a final rejection to Pierre Fabre's bladder cancer drug Javior. Report

> Sanofi's ($SNY) Israeli unit is shopping for a consumer healthcare company there, aiming for a deal in the "several tens of millions." Report

> Slovenia's Krka saw net profits drop by 3%, but officials expect a 6% increase in sales for 2013, to €1.2 billion ($1.5 billion), and plan new hires and new plants at home and in Russia. Report

Medical Device News

 @FierceMedDev: As advocates fight to repeal the device tax, we take a detailed look at how the 2.3% charge would work. Special Report | Follow @FierceMedDev

 @MarkHFierce: Hansen Medical, maker of the Magellan Surgical Robot, raised $10M in a new offering. More | Follow @MarkHFierce

 @DamianFierce: Roche Diagnostics broke ground on the first phase of its $300M Indianapolis expansion. News | Follow @DamianFierce

> Study: CardioDx's test helps guide cardiology decisions. Story

> Report: U.S. government incentives will spur robust infusion pump sales. Item

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: PPD secures adaptive trials software as clinical studies evolve. More | Follow @FierceBiotech

 @JohnCFierce: After FDA rejection, Bristol-AstraZeneca team wins E.C. OK for diabetes drug dapagliflozin--new hope for SGLT2 drugs. News | Follow @JohnCFierce

 @RyanMFierce: 10 trends in diagnostics from FierceBiotech. #1: Companion Dx. Special Report | Follow @RyanMFierce

> Sanofi's new CSO to steer R&D reinvention drive from Cambridge, MA office. Report

> Troubled Tranzyme reports another key clinical trial failure. News

> Upstart Valor launches with plans to develop armed antibody cancer drugs. Article

Pharma Manufacturing News

> Call for counterfeit drug treaty gets group banned from WHO event. Article

> Regeneron invests $80 million in plant, office project. News

> Promega expands with new China plant. Item

> Genzyme manufacturing upgrades again paying off. Story

Vaccines News

 @AlisonBFierce: Inovio Pharmaceuticals, a developer of synthetic vaccines, expanded its existing license agreement with UPenn. More | Follow @AlisonBFierce

> FDA: Dynavax's Heplisav effective against hepatitis B. Report

> Meningitis vaccine ruled safe for warm storage. Article

> Takeda sets sights on the vaccine market. More

> GSK's rotavirus vaccine selected for British program. News

> GSK reports lackluster PhIII malaria vaccine data. Story

And Finally... Beta blockers, used to treat high blood pressure, are considered performance-enhancers in professional golf. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.